Masahito Kawazu
University of Tokyo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Masahito Kawazu.
Journal of Clinical Microbiology | 2004
Masahito Kawazu; Yoshinobu Kanda; Yasuhito Nannya; Katsunori Aoki; Mineo Kurokawa; Shigeru Chiba; Toru Motokura; Hisamaru Hirai; Seishi Ogawa
ABSTRACT The establishment of an optimal noninvasive method for diagnosing invasive aspergillosis (IA) is needed to improve the management of this life-threatening infection in patients with hematological disorders, and a number of noninvasive tests for IA that target different fungal components, including galactomannan, (1→3)-β-d-glucan (BDG), and Aspergillus DNA, have been developed. In this study, we prospectively evaluated the diagnostic potential of three noninvasive tests for IA that were used in a weekly screening strategy: the double-sandwich enzyme-linked immunosorbent assay (ELISA) for galactomannan (Platelia Aspergillus), a real-time PCR assay for Aspergillus DNA (GeniQ-Asper), and an assay for BDG (β-glucan Wako). We analyzed 149 consecutive treatment episodes in 96 patients with hematological disorders who were at high risk for IA and diagnosed 9 proven IA cases, 2 probable IA cases, and 13 possible invasive fugal infections. In a receiver-operating characteristic (ROC) analysis, the area under the ROC curve was greatest for ELISA, using two consecutive positive results (0.97; P = 0.036 for ELISA versus PCR, P = 0.055 for ELISA versus BDG). Based on the ROC curve, the cutoff for the ELISA could be reduced to an optical density index (O.D.I.) of 0.6. With the use of this cutoff for ELISA and cutoffs for PCR and BDG that give a comparable level of specificity, the sensitivity/specificity/positive predictive value/negative predictive value of the ELISA and the PCR and BDG tests were 1.00/0.93/0.55/1.00, 0.55/0.93/0.40/0.96, and 0.55/0.93/0.40/0.96, respectively. In conclusion, among these weekly screening tests for IA, the double-sandwich ELISA test was the most sensitive at predicting the diagnosis of IA in high-risk patients with hematological disorders, using a reduced cutoff of 0.6 O.D.I.
Journal of Immunology | 2008
Motoshi Ichikawa; Susumu Goyama; Takashi Asai; Masahito Kawazu; Masahiro Nakagawa; Masataka Takeshita; Shigeru Chiba; Seishi Ogawa; Mineo Kurokawa
Transcription factor AML1/Runx1, initially isolated from the t(8;21) chromosomal translocation in human leukemia, is essential for the development of multilineage hematopoiesis in mouse embryos. AML1 negatively regulates the number of immature hematopoietic cells in adult hematopoiesis, whereas it is required for megakaryocytic maturation and lymphocytic development. However, it remains yet to be determined how AML1 contributes to homeostasis of hematopoietic stem cells (HSCs). To address this issue, we analyzed in detail HSC function in the absence of AML1. Notably, cells in the Hoechst 33342 side population fraction are increased in number in AML1-deficient bone marrow, which suggests enrichment of quiescent HSCs. We also found an increase in HSC number within the AML1-deficient bone marrow using limiting dilution bone marrow transplantation assays. These results indicate that the number of quiescent HSCs is negatively regulated by AML1.
Proceedings of the National Academy of Sciences of the United States of America | 2013
Masahito Kawazu; Toshihide Ueno; Kenji Kontani; Yoshitaka Ogita; Mizuo Ando; Kazutaka Fukumura; Azusa Yamato; Manabu Soda; Kengo Takeuchi; Yoshio Miki; Hiroyuki Yamaguchi; Takahiko Yasuda; Tomoki Naoe; Yoshihiro Yamashita; Toshiaki Katada; Young Lim Choi; Hiroyuki Mano
Members of the RAS superfamily of small guanosine triphosphatases (GTPases) transition between GDP-bound, inactive and GTP-bound, active states and thereby function as binary switches in the regulation of various cellular activities. Whereas HRAS, NRAS, and KRAS frequently acquire transforming missense mutations in human cancer, little is known of the oncogenic roles of other small GTPases, including Ras-related C3 botulinum toxin substrate (RAC) proteins. We show that the human sarcoma cell line HT1080 harbors both NRAS(Q61K) and RAC1(N92I) mutant proteins. Whereas both of these mutants were able to transform fibroblasts, knockdown experiments indicated that RAC1(N92I) may be the essential growth driver for this cell line. Screening for RAC1, RAC2, or RAC3 mutations in cell lines and public databases identified several missense mutations for RAC1 and RAC2, with some of the mutant proteins, including RAC1(P29S), RAC1(C157Y), RAC2(P29L), and RAC2(P29Q), being found to be activated and transforming. P29S, N92I, and C157Y mutants of RAC1 were shown to exist preferentially in the GTP-bound state as a result of a rapid transition from the GDP-bound state, rather than as a result of a reduced intrinsic GTPase activity. Activating mutations of RAC GTPases were thus found in a wide variety of human cancers at a low frequency; however, given their marked transforming ability, the mutant proteins are potential targets for the development of new therapeutic agents.
Journal of Immunology | 2005
Sachiko Seo; Takashi Asai; Toshiki Saito; Takahiro Suzuki; Yasuyuki Morishita; Tetsuya Nakamoto; Motoshi Ichikawa; Go Yamamoto; Masahito Kawazu; Tetsuya Yamagata; Ryuichi Sakai; Kinuko Mitani; Seishi Ogawa; Mineo Kurokawa; Shigeru Chiba; Hisamaru Hirai
The lymphocyte-specific Cas family protein Cas-L (Crk-associated substrate lymphocyte type) has been implicated to function in lymphocyte movement, mediated mainly by integrin signaling. However, its physiological role is poorly understood. In this study we analyzed the function of Cas-L in lymphocytes using gene-targeted mice. The mutant mice showed a deficit of marginal zone B (MZB) cells and a decrease of cell number in secondary lymphoid organs. An insufficient chemotactic response and perturbed cell adhesion were observed in Cas-L-deficient lymphocytes, suggesting that the aberrant localization was responsible for the deficit of MZB cells. Moreover, we found that lymphocyte trafficking was altered in Cas-L-deficient mice, which gave a potential reason for contraction of secondary lymphoid tissues. Thus, Cas-L affects homeostasis of MZB cells and peripheral lymphoid organs, which is considered to be relevant to impaired lymphocyte migration and adhesion.
Nature Genetics | 2016
Takahiko Yasuda; Shinobu Tsuzuki; Masahito Kawazu; Fumihiko Hayakawa; Shinya Kojima; Toshihide Ueno; Naoto Imoto; Shinji Kohsaka; Akiko Kunita; Koichiro Doi; Toru Sakura; Toshiaki Yujiri; Eisei Kondo; Katsumichi Fujimaki; Yasunori Ueda; Yasutaka Aoyama; Shigeki Ohtake; Junko Takita; Eirin Sai; Masafumi Taniwaki; Mineo Kurokawa; Shinichi Morishita; Masashi Fukayama; Hitoshi Kiyoi; Yasushi Miyazaki; Tomoki Naoe; Hiroyuki Mano
The oncogenic mechanisms underlying acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYA; 15–39 years old) remain largely elusive. Here we have searched for new oncogenes in AYA-ALL by performing RNA-seq analysis of Philadelphia chromosome (Ph)-negative AYA-ALL specimens (n = 73) with the use of a next-generation sequencer. Interestingly, insertion of D4Z4 repeats containing the DUX4 gene into the IGH locus was frequently identified in B cell AYA-ALL, leading to a high level of expression of DUX4 protein with an aberrant C terminus. A transplantation assay in mice demonstrated that expression of DUX4-IGH in pro-B cells was capable of generating B cell leukemia in vivo. DUX4 fusions were preferentially detected in the AYA generation. Our data thus show that DUX4 can become an oncogenic driver as a result of somatic chromosomal rearrangements and that AYA-ALL may be a clinical entity distinct from ALL at other ages.
Leukemia & Lymphoma | 2002
Susumu Goyama; Yoshinobu Kanda; Yasuhito Nannya; Masahito Kawazu; Masataka Takeshita; Miyuki Niino; Yukiko Komeno; Tetsuya Nakamoto; Mineo Kurokawa; Shiho Tsujino; Seishi Ogawa; Katsunori Aoki; Shigeru Chiba; Toru Motokura; Y. Shiratori; Hisamaru Hirai
Hepatitis B virus (HBV) reactivation in patients previously positive for hepatitis B surface antibody (HBsAb), so-called reverse seroconversion, has been considered to be a rare complication after hematopoietic stem cell transplantation (HSCT). We experienced two patients who developed reverse seroconversion among nine who were HBsAb positive and Hepatitis B core antibody (HBcAb) positive before HSCT; one after autologous bone marrow transplantation (BMT) and another after allogeneic peripheral blood stem cell transplantation (PBSCT). We reviewed the literature and considered that reverse seroconversion of HBV after HSCT is not uncommon among HBsAb positive recipients. The use of corticosteroids, the lack of HBsAb in donor, and a decrease in serum HBsAb and HBcAb levels may predict reverse seroconversion after HSCT.
Nature Communications | 2014
Akihide Yoshimi; Takashi Toya; Masahito Kawazu; Toshihide Ueno; Ayato Tsukamoto; Hiromitsu Iizuka; Masahiro Nakagawa; Yasuhito Nannya; Shunya Arai; Hironori Harada; Kensuke Usuki; Yasuhide Hayashi; Etsuro Ito; Keita Kirito; Hideaki Nakajima; Motoshi Ichikawa; Hiroyuki Mano; Mineo Kurokawa
Familial platelet disorder (FPD) with predisposition to acute myelogenous leukaemia (AML) is characterized by platelet defects with a propensity for the development of haematological malignancies. Its molecular pathogenesis is poorly understood, except for the role of germline RUNX1 mutations. Here we show that CDC25C mutations are frequently found in FPD/AML patients (53%). Mutated CDC25C disrupts the G2/M checkpoint and promotes cell cycle progression even in the presence of DNA damage, suggesting a critical role for CDC25C in malignant transformation in FPD/AML. The predicted hierarchical architecture shows that CDC25C mutations define a founding pre-leukaemic clone, followed by stepwise acquisition of subclonal mutations that contribute to leukaemia progression. In three of seven individuals with CDC25C mutations, GATA2 is the target of subsequent mutation. Thus, CDC25C is a novel gene target identified in haematological malignancies. CDC25C is also useful as a clinical biomarker that predicts progression of FPD/AML in the early stage.
Journal of Immunology | 2005
Masahito Kawazu; Takashi Asai; Motoshi Ichikawa; Go Yamamoto; Toshiki Saito; Susumu Goyama; Kinuko Mitani; Kohei Miyazono; Shigeru Chiba; Seishi Ogawa; Mineo Kurokawa; Hisamaru Hirai
Runx1 (AML1) has multiple functions in thymocyte development, including CD4 repression in immature thymocytes, expression of TCRβ, and efficient β-selection. To determine the functional domains of Runx1 important for thymocyte development, we cultured Runx1-deficient murine fetal liver (FL) cells on OP9-Delta-like 1 murine stromal cells, which express Delta-like 1 and support thymocyte development in vitro, and introduced Runx1 or C-terminal-deletion mutants of Runx1 into the FL cells by retrovirus infection. In this system, Runx1-deficient FL cells failed to follow normal thymocyte development, whereas the introduction of Runx1 into the cells was sufficient to produce thymocyte development that was indistinguishable from that in wild-type FL cells. In contrast, Runx1 mutants that lacked the activation domain necessary for initiating gene transcription did not fully restore thymocyte differentiation, in that it neither repressed CD4 expression nor promoted the CD4/8 double-negative to CD4/8 double-positive transition. Although the C-terminal VWRPY motif-deficient mutant of Runx1, which cannot interact with the transcriptional corepressor Transducin-like enhancer of split (TLE), promoted the double-negative to double-positive transition, it did not efficiently repress CD4 expression. These results suggest that the activation domain is essential for Runx1 to establish thymocyte development and that Runx1 has both TLE-dependent and TLE-independent functions in thymocyte development.
Cancer Science | 2008
Tomohiko Sato; Susumu Goyama; Eriko Nitta; Masataka Takeshita; Mayumi Yoshimi; Masahiro Nakagawa; Masahito Kawazu; Motoshi Ichikawa; Mineo Kurokawa
Evi‐1 is a zinc‐finger transcriptional factor whose inappropriate expression leads to leukemic transformation in mice and humans. Recently, it has been shown that Evi‐1 regulates proliferation of hematopoietic stem/progenitor cells at embryonic stage via GATA‐2 up‐regulation; however, detailed mechanisms underlying Evi‐1‐mediated early hematopoiesis are not fully understood. We therefore evaluated hematopoietic potential of Evi‐1 mutants using a cultivation system of murine para‐aortic splanchnopleural (P‐Sp) regions, and found that both the first zinc finger domain and the acidic domain were required for Evi‐1‐mediated hematopoiesis. The hematopoietic potential of Evi‐1 mutants was likely to be related to its ability to up‐regulate GATA‐2 expression. We also showed that the decreased colony forming capacity of Evi‐1‐deficient P‐Sp cells was successfully recovered by inhibition of TGF‐b signaling, using ALK5 inhibitor or retroviral transfer of dominant‐negative‐type Smad3. Our findings suggest that Evi‐1 promotes hematopoietic stem/progenitor expansion at the embryonic stage through up‐regulation of GATA‐2 and repression of TGF‐b signaling. (Cancer Sci 2008; 99: 1407–1413)
Leukemia | 2014
Takahiko Yasuda; Toshihide Ueno; Kazutaka Fukumura; Azusa Yamato; Mizuo Ando; Hiroyuki Yamaguchi; Manabu Soda; Masahito Kawazu; Eirin Sai; Yoshihiro Yamashita; Makoto Murata; Hitoshi Kiyoi; Tomoki Naoe; Hiroyuki Mano
Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation